BACKGROUND: Nucleophosmin 1 (NPM1) is one of the most commonly mutated genes in acute myeloid leukemia, with mutations observed in approximately 30% of all adult cases. The persistence of NPM1 mutations following chemotherapy is associated with a greater risk of relapse as well as a lower rate of survival, making NPM1 measurable residual disease (MRD) an informative clinical target. METHODS: Herein, we have developed a straightforward unique molecular identifier (UMI)-based amplicon next-generation sequencing method for the detection of NPM1-mutated MRD that addresses some of the limitations present in other assays. RESULTS: The NPM1 assay allowed for accurate counting of individual mutant and wild-type molecules down to 0.01% variant allelic frequency. In silico contamination experiments highlighted the ability of this UMI methodology to maximize specificity through dramatic reductions in sequencing/demultiplexing bleed-through error. CONCLUSION: Performance and clinical utility of the NPM1 MRD assay are established via both validation experiments and analyses of live performance over 1.5 years of routine clinical service.
BACKGROUND:Nucleophosmin 1 (NPM1) is one of the most commonly mutated genes in acute myeloid leukemia, with mutations observed in approximately 30% of all adult cases. The persistence of NPM1 mutations following chemotherapy is associated with a greater risk of relapse as well as a lower rate of survival, making NPM1 measurable residual disease (MRD) an informative clinical target. METHODS: Herein, we have developed a straightforward unique molecular identifier (UMI)-based amplicon next-generation sequencing method for the detection of NPM1-mutated MRD that addresses some of the limitations present in other assays. RESULTS: The NPM1 assay allowed for accurate counting of individual mutant and wild-type molecules down to 0.01% variant allelic frequency. In silico contamination experiments highlighted the ability of this UMI methodology to maximize specificity through dramatic reductions in sequencing/demultiplexing bleed-through error. CONCLUSION: Performance and clinical utility of the NPM1 MRD assay are established via both validation experiments and analyses of live performance over 1.5 years of routine clinical service.
Authors: Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: N I Noguera; E Ammatuna; D Zangrilli; S Lavorgna; M Divona; F Buccisano; S Amadori; C Mecucci; B Falini; F Lo-Coco Journal: Leukemia Date: 2005-08 Impact factor: 11.528
Authors: Roel G W Verhaak; Chantal S Goudswaard; Wim van Putten; Maarten A Bijl; Mathijs A Sanders; Wendy Hugens; André G Uitterlinden; Claudia A J Erpelinck; Ruud Delwel; Bob Löwenberg; Peter J M Valk Journal: Blood Date: 2005-08-18 Impact factor: 22.113
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Erik B R Malmberg; Sara Ståhlman; Anna Rehammar; Tore Samuelsson; Sofie J Alm; Erik Kristiansson; Jonas Abrahamsson; Hege Garelius; Louise Pettersson; Mats Ehinger; Lars Palmqvist; Linda Fogelstrand Journal: Eur J Haematol Date: 2016-06-08 Impact factor: 2.997
Authors: Jan Krönke; Lars Bullinger; Veronica Teleanu; Florian Tschürtz; Verena I Gaidzik; Michael W M Kühn; Frank G Rücker; Karlheinz Holzmann; Peter Paschka; Silke Kapp-Schwörer; Daniela Späth; Thomas Kindler; Marcus Schittenhelm; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Richard F Schlenk; Hartmut Döhner; Konstanze Döhner Journal: Blood Date: 2013-05-23 Impact factor: 22.113
Authors: Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade Journal: N Engl J Med Date: 2016-01-20 Impact factor: 91.245
Authors: Amanda Lopez; Sanjay Patel; Julia T Geyer; Joelle Racchumi; Amy Chadburn; Paul Simonson; Madhu M Ouseph; Giorgio Inghirami; Nuria Mencia-Trinchant; Monica L Guzman; Alexandra Gomez-Arteaga; Sangmin Lee; Pinkal Desai; Ellen K Ritchie; Gail J Roboz; Wayne Tam; Michael J Kluk Journal: Front Oncol Date: 2021-08-30 Impact factor: 6.244
Authors: Sanam Loghavi; Courtney D DiNardo; Ken Furudate; Koichi Takahashi; Tomoyuki Tanaka; Nicholas J Short; Tapan Kadia; Marina Konopleva; Rashmi Kanagal-Shamanna; Noushin R Farnoud; Sherry Pierce; Joseph D Khoury; Jeffrey L Jorgensen; Keyur P Patel; Naval Daver; Musa Yilmaz; L Jeffrey Medeiros; Hagop Kantarjian; Farhad Ravandi; Sa A Wang Journal: Br J Haematol Date: 2021-02-22 Impact factor: 6.998